Dehydrogenase reductase 9 (SDR9C4) and related homologs recognize a broad spectrum of lipid mediator oxylipins as substrates

Received for publication, October 5, 2021, and in revised form, December 13, 2021 Published, Papers in Press, December 22, 2021, https://doi.org/10.1016/j.jbc.2021.101527

Olga V. Belyaeva, Samuel E. Wirth, William E. Boeglin, Suman Karki, Kelli R. Goggans, Stacy G. Wendell, Kirill M. Popov, Alan R. Brash, and Natalia Y. Kedishvili

From the \(^1\)Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA; \(^2\)Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA; \(^3\)Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Edited by Dennis Voelker

Bioactive oxylipins play multiple roles during inflammation and in the immune response, with termination of their actions partly dependent on the activity of yet-to-be characterized dehydrogenases. Here, we report that human microsomal dehydrogenase reductase 9 (DHR9, also known as SDR9C4 of the short-chain dehydrogenase/reductase (SDR) superfamily) exhibits a robust oxidative activity toward oxylipins with hydroxyl groups located at carbons C9 and C13 of octadecanoids, C12 and C15 carbons of eicosanoids, and C14 carbon of docosanoids. DHR9/SDR9C4 is also active toward lipid in-

Typically, these proteins function as dimeric or tetrameric NAD(P)(H)-dependent oxidoreductases with a subunit molecular mass of 25 to 35 kDa. SDR enzymes are found in the cytoplasm, mitochondria, nuclei, peroxisomes, and endoplasmic reticulum where they participate in the metabolism of sugars, steroids, prostaglandins, retinoids, aliphatic alcohols, and xenobiotics.

DHR9 belongs to SDR9C, the largest subfamily of SDRs with many as eight human members and at least 13 mouse homologs. The additional mouse homologs likely appeared as a result of multiple rounds of lineage-specific gene duplications (Fig. 1) (3, 4). The two founding members were named retinol dehydrogenases (RDH), based on the initial assays that demonstrated their activities toward 11-cis-retinol (human RDH5), (5) and all-trans-retinol (rat RDH7) (6). However, later analysis revealed that both RDH5 and RDH7 displayed activities toward 3α-hydroxysteroids (7, 8). In the case of rat RDH7, its 3α-hydroxysteroid dehydrogenase activity significantly exceeded that with all-trans-retinol. Similarly, human homologs of rat RDH7, i.e., human RDH16 (SDR9C8), which shares 72% protein sequence identity with rat RDH7, and human 17β-hydroxysteroid dehydrogenase 6 (HSD17B6/SDR9C6) with 66% sequence identity (Fig. 1) to rat RDH7 were shown to oxidize the hydroxyl groups on steroid molecules (9, 10).

Furthermore, like human RDH5 and rat RDH7, human RDH16 and HSD17B6 were also capable of oxidizing retinoid substrates, suggesting that active sites of these enzymes can accommodate structurally unrelated substrates (names of these SDRs assigned by different researchers who independently cloned the corresponding genes are listed in Table S1).

Although in vitro human RDH5 (SDR9C5) displays dual substrate specificity toward 11-cis-retinol and 3α-hydroxysteroids, its in vivo role in the oxidation of 11-cis-retinol to 11-cis-retinaldehyde in the visual cycle has been supported by genetic linkage evidence (11) and gene knockout analysis in a mouse model [reviewed in ref. (12)]. In addition to the established role of RDH5 in 11-cis-retinol metabolism, a recent study uncovered the role of SDR9C7, previously known as SDR-orphan (SDR-O), in dehydrogenation of acylceramides for skin

The short-chain dehydrogenase/reductase (SDR) superfamily of proteins is comprised of over 47,000 members that are found in all forms of life (1–3). Members are assigned on the basis of SDR signature features, including the TGX3GXG motif of the nucleotide-binding region and the catalytically active tetrad N-S-Y-K, which constitutes the active site.

For correspondence: Natalia Y. Kedishvili, nkedishvili@uab.edu.
Oxylipin dehydrogenase activity of DHR9

Figure 1. Phylogenetic tree of human and rodent members of the SDR9C family of proteins. The phylogeny of SDR9C family was inferred using the Neighbor-Joining method (52). The optimal tree is shown. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Poisson correction method and are in the units of the number of amino acid substitutions per site. This analysis involved 24 amino acid sequences. There were a total of 489 positions in the final dataset. Analysis was conducted in MEGA X (53). Proteins investigated in this study are highlighted in red font.

With steroid substrates and little if any activity with retinoid substrates, these findings suggested that DHR9 might naturally utilize substrates other than steroids and/or retinoids.

Considering that human DHR9 mRNA has a broad tissue distribution pattern (15), and the expression of DHR9 is frequently altered during tissue inflammation and/or carcinogenesis as well as in metabolic disorders and obesity (24–33), we reinvestigated the substrate specificity of human and rodent DHR9. The results of this study suggest an evolutionarily conserved role for DHR9 in the oxidative metabolism of a broad range of bioactive oxylipins.

Results

Substrate specificity of SDR9C family member DHR9 (SDR9C4)

Human DHR9 (SDR9C4) was expressed in Sf9 cells using the baculovirus expression system, and the microsomes were isolated for kinetic analysis. In addition to DHR9, other members of SDR9C family with reported retinoid and hydroxysteroid activities, i.e., human RDH16 (9), human HSD17B6 (10), and rat RDH7 (8) were assayed with the same set of previously untested substrates.

The relative levels of each protein in Sf9 microsomes were assessed using Coomassie Blue stained SDS-PAGE gels (Fig. 2A). The identities of each SDR were verified by Western blotting (Fig. 2, B and C) and quantified by scanning densitometry. Although the microsomal preparations contained somewhat different protein amounts of individual SDRs, considering that protein levels of RDH16, DHR9, and RDH7 were fairly close, some ideas about their relative catalytic efficiencies and substrate specificities can be drawn from the kinetic parameters.

As summarized in Table 1, DHR9 displayed a very robust activity toward hydroxylated oxylipins (structures of substrates tested are shown in Fig. S1). Of significance regarding substrate specificity, within the arachidonic acid series of HETEs, we were unable to detect any activity with 5(S)-HETE, whereas both 12(S)-HETE and 15(S)-HETE were well oxidized, suggesting that DHR9 preferentially oxidizes secondary alcohol groups located along the CH3-terminal tail of the carbon chain. This was supported by the relative oxidation rates of the two hydroxy-C18:2 ω6 oxylipins: both were effective substrates, with a fivefold higher rate for 13(S)-HODE compared with 9(S)-HODE. In line with this specificity, 14(S)-HDOHE of the C22:6ω3 series was also a good substrate.

With polyhydroxylated substrates (Fig. S1), DHR9 demonstrated the greatest \( V_{\text{max}} \) value toward LXA4, followed by LTB4 and RvD1 in the order: LXA4 > LTB4 >> RvD1. However, its \( K_m \) value for LXA4 was sixfold greater than that for LTB4 (Table 1). Consequently, the catalytic efficiency (\( V_{\text{max}}/K_m \)) of DHR9 for LTB4 exceeded that of LXA4 and RvD1 by a factor of 4.5 and 4.2, respectively, suggesting that among LXA4, LTB4, and RvD1, LTB4 might be the preferred substrate of human DHR9.

In designating DHR9-catalyzed oxidation to classes of potential substrates, it is notable that the activity with the top
Oxylipin dehydrogenase activity of DHRS9

Table 1
Substrate specificity of human DHRS9 (SDR9C4)

| Substrate          | $K_{m}$ $\mu$M | $V_{max}$ a, pmol $\times$ min $^{-1}$ | $V_{max}/K_{m}$ pmol/(min $\times$ $\mu$M) |
|--------------------|----------------|----------------------------------------|-------------------------------------------|
| 12(S)-HETE         | 0.43 ± 0.16    | 220 ± 33                                | 512                                       |
| 15(S)-HETE         | 0.36 ± 0.18    | 140 ± 21                                | 390                                       |
| 9(S)-HODE          | 0.57 ± 0.25    | 24 ± 3                                  | 42                                        |
| 13(S)-HODE         | 0.46 ± 0.19    | 110 ± 14                                | 240                                       |
| 14(S)-HDdoHE       | 0.17 ± 0.06    | 80 ± 8                                  | 471                                       |
| LTB4               | 0.76 ± 0.44    | 170 ± 43                                | 224                                       |
| LXA4               | 4.6 ± 2.7      | 230 ± 76                                | 50                                        |
| RvD1               | 1.6 ± 0.5      | 85 ± 12                                 | 53                                        |
| All-trans-retinol  | ND             | 0.32 b                                  | -                                         |
| Androsterone       | ND             | 6.8 c                                   | -                                         |

Abbreviation: ND, not determined.

a To facilitate the comparison of catalytic efficiency of DHRS9 toward various oxylipin substrates, its $V_{max}$ values were calculated based on the activity in samples containing 1 $\mu$g of total microsomal protein.

b The reaction rate was determined using 10 $\mu$M all-trans-retinol and 1 mM NAD$^+$ with 5 $\mu$g of DHRS9 Sf9 microsomes.

c The reaction rate was determined using 20 $\mu$g androsterone and 1 mM NAD$^+$ with 5 $\mu$g of DHRS9 Sf9 microsomes.

Oxylipin substrates greatly exceeded the rates with androsterone and all-trans-retinol, by 20-fold and 500-fold, respectively, compared with 12(S)-HETE (Table 1 and Fig. S2). These observations strongly suggest that hydroxylated oxylipins are the preferred, natural substrates of DHRS9.

Figure 2. Expression of SDR9C proteins in Sf9 microsomes. A, Coomassie Blue-stained SDS-PAGE gel. Fifty micrograms of Sf9 microsomes containing different recombinant proteins were loaded into each lane. RDH10 microsomes were loaded as a negative control. The positions of each recombinant protein are indicated by the red boxes. Based on scanning densitometry, the protein content of each SDR in microsomal preparations relative to human RDH16, which was set as 1, was as follows: 3.15-fold higher for human HSD17B6, 1.63-fold higher for rat RDH7, and 1.6-fold higher for human RDH16. B, Western blot analysis of the same set of microsomal preparations (0.5 $\mu$g/lane) using human RDH16 (RoDH4) antibodies (N-terminal M17, 1:5000) (9). Note that the antibodies detect human HSD17B6 protein and also weakly react with rat RDH7. C, Western blot analysis of the same set of microsomal preparations (0.5 $\mu$g/lane) using DHRS9 antibodies (Abclonal, 1:2000).

Oxylipin substrates greatly exceeded the rates with androsterone and all-trans-retinol, by 20-fold and 500-fold, respectively, compared with 12(S)-HETE (Table 1 and Fig. S2). These observations strongly suggest that hydroxylated oxylipins are the preferred, natural substrates of DHRS9.

Comparable studies with the mouse enzyme used microsomes from DHRS9-expressing HEK293 cells. Qualitatively, the activity on oxylipins was similar to the human enzyme (Fig. 3 and Table 2). Among the monohydroxylated oxylipins, the highest rate of conversion was observed with 12(S)-HETE. 15(S)-HETE, 9(S)-HODE, and 13(S)-HODE were oxidized at approximately similar rates that were about twofold lower than with 12(S)-HETE (Table 2). With polyhydroxylated substrates, mouse DHRS9 demonstrated the highest oxidation rate toward 17(R)-RvD1, followed by LTB4. The reaction rate was about threefold lower with 1 $\mu$M LXA4 as substrate compared with 1 $\mu$M RvD1, and no activity was detected toward LXB4. On account of the relatively low expression level in HEK293 cells, a means to quantify mouse DHRS9 protein levels was lacking, obviating direct comparison of rates with human DHRS9, although the substrate specificities were an excellent match.

Substrate specificity of RDH16 (SDR9C8)

Similar analysis carried out with another member of the SDR9C family human RDH16 (SDR9C8) yielded significant differences. Although 15(S)-HETE and the two C18:2 HODEs were oxidized by RDH16 (Table 3), the enzyme displayed 1 to 2 orders of magnitude lower rates compared with DHRS9, even after accounting for the 1.6-fold lower level of RDH16 protein expression in Sf9 microsomes (see Fig. 2A); furthermore, there was negligible activity with 12(S)-HETE. RDH16 also exhibited marginal activities with LTB4, LXA4, RvD1, and all-trans-retinol, making it highly unlikely that RDH16 can successfully compete in vivo with DHRS9 for these oxylipins, or with RDH10, the proven retinol dehydrogenase (22), for all-trans-retinol.

In fact, the $V_{max}/K_{m}$ values of RDH16 for monohydroxylated oxylipins were lower than its $V_{max}/K_{m}$ value for androsterone (Table 3 and Fig. S2) that we reported previously (34). Taken together, these observations suggest that it is highly unlikely that RDH16 can directly compete for monohydroxylated oxylipins with DHRS9 or for androsterone with other more specialized sterol dehydrogenases. It is still possible that RDH16 might occupy some specialized niche where it can
metabolize oxylipins and/or steroids without directly competing with other better suited enzymes. Alternatively, it might indicate that natural substrates of RDH16 remain to be identified.

Substrate specificity of human HSD17B6 (SDR9C6)

Kinetic analysis of human HSD17B6 revealed marginal activities with the majority of oxylipin substrates as well as with all-trans-retinol (Table 4). Therefore, it is highly unlikely that HSD17B6 can compete with DHRS9 for any biologically active oxylipin substrates. It is also unlikely that HSD17B6 can compete with specialized retinol dehydrogenases, like RDH10, for all-trans-retinol. In fact, these outcomes are not particularly surprising because our earlier study (10) had demonstrated that HSD17B6 acts as a robust sterol dehydrogenase showing high catalytic efficiency for androsterone (see Table 3 and Fig. S2).

Substrate specificity of rat RDH7

Rat RDH7 is a homolog of human RDH16 (Fig. 1). This enzyme displayed only marginal activities with poly-hydroxylated oxylipin substrates (Table 5). However, similar to human RDH16, rat RDH7 could oxidize some of mono-hydroxylated oxylipins such as 9(S)-HODE, 15(S)-HETE, and 12(S)-HETE. Furthermore, unlike human RDH16, which had

---

**Table 2**

Activity of mouse DHRS9 toward oxylipins

| Substrate     | Product     | Rate, nmol × min⁻¹ × mg⁻¹ of microsomal protein |
|---------------|-------------|-----------------------------------------------|
| 12(S)-HETE    | 12-oxo-ETE  | 1.9 ± 0.2                                     |
| 15(S)-HETE    | 15-oxo-ETE  | 1.1 ± 0.1                                     |
| 9(S)-HODE     | 9-KODE      | 0.82 ± 0.05                                   |
| 13(S)-HODE    | 13-KODE     | 0.70 ± 0.03                                   |
| RvD1          | Oxo-RvD1    | 1.2 ± 0.1                                     |
| 17(R)-RvD1    | Oxo-RvD1    | 1.3 ± 0.1                                     |
| LXA₄          | Oxo-LXA₄    | 0.30 ± 0.02                                   |
| LXB₄          | Oxo-LTB₄    | 0.0                                           |
| LTB₄          | Oxo-LTB₄    | 0.88 ± 0.04                                   |

Microsomes (5 μg) isolated from HEK293 cells transfected with mouse DHRS9 expression construct were incubated with substrates (1 μM each) as indicated. The reaction products were extracted and analyzed as described under Experimental procedures. The values represent the reaction rates after subtracting the rates obtained with microsomes from HEK293 cells transfected with empty vector.

---

**Figure 3. Characterization of mouse DHRS9 activities towards oxylipins.**

A. Western blot analysis of mouse DHRS9 expression in HEK 293 cells. HEK 293 cells were transiently transfected with mouse DHRS9 expression construct. HEK293 microsomes (30 μg) containing DHRS9 protein were analyzed by Western blotting using DHRS9 antibodies (Abclonal, 1:2000). Immunodetection with cytochrome P450 reductase antibodies (#13513 Abcam, 1:1000) was used for a gel loading control. B–H. Activities of mouse DHRS9. Microsomes (5 μg) isolated from HEK293 cells transfected with either empty vector (black traces) or mouse Dhrs9 expression construct (red traces) were incubated with substrates (1 μM each) as indicated. The reaction products were extracted and analyzed as described under Experimental procedures. **Top panels**—chromatograms extracted at the λ_MAX of the substrate, **bottom panels**—at λ_MAX of the product. Note the appearance of the oxidized products in the presence of DHRS9. Insets, spectra for substrates (black) and products (red).
Kₘ values in the range of 1.5 to 2 μM, rat RDH7 displayed low, submicromolar Kₘ values for 9(S)-HODE and 15(S)-HETE (0.1–0.2 μM), making it fairly specific for these substrates.

In addition to 9(S)-HODE and 15(S)-HETE, rat RDH7 showed a very high activity toward androsterone (Fig. S2), suggesting that, in vivo, in addition to the metabolism of oxylipins, rat RDH7 might also contribute to the metabolism of sterols. Lastly, RDH7 activity toward all-trans-retinol was rather modest (Table 5), making it fairly unlikely that it contributes to the retinoid metabolism in vivo.

In addition to the four members of the SDR9C family, we analyzed the ability of several other SDRs from different families to utilize oxylipin substrates. We were unable to detect an appreciable activity for these substrates with retinoid-active SDRs such as human RH9D10 (SDR16C4) (35) and RDH5 (SDR9C5) (5) or steroid-active SDR HSD11B1 (SDR26C1) (data not shown).

### Table 3

Substrate specificity of human RH9D16 (SDR9C8)

| Substrate | Kₘ μM | Vₘₕ, pmol × min⁻¹ | Vₘₕ/Kₘ pmol/(min × μM) |
|-----------|-------|---------------------|------------------------|
| 12(S)-HETE | 2.01 ± 0.64 | 2.15 ± 0.24 | 1 |
| 15(S)-HETE | 1.39 ± 0.56 | 20.43 ± 3.29 | 15 |
| 9(S)-HODE | 1.76 ± 0.59 | 16.72 ± 1.88 | 10 |
| 13(S)-HODE | 0.83 ± 0.36 | 7.70 ± 1.16 | 9 |
| LTB₄ | ND | 1.22 | - |
| LXA₄ | ND | 1.1 | - |
| RvD1 | ND | 0.21 | - |
| All-trans-retinol | ND | 0.97 | 0.1 |
| Androsterone | ND | 5.2 | 24 |

Abbreviation: ND, not determined.

### Table 4

Substrate specificity of human HSD17B6 (SDR9C6)

| Substrate | Kₘ μM | Vₘₕ, pmol × min⁻¹ | Vₘₕ/Kₘ pmol/(min × μM) |
|-----------|-------|---------------------|------------------------|
| 12(S)-HETE | 0.87 ± 0.35 | 7.96 ± 0.89 | 9 |
| 15(S)-HETE | 1.78 ± 0.42 | 2.88 ± 0.23 | 1.6 |
| 9(S)-HODE | 0.64 ± 0.28 | 0.40 ± 0.05 | 0.6 |
| 13(S)-HODE | 0.33 ± 0.24 | 0.9 ± 0.2 | 2.7 |
| LTB₄ | ND | 0.13 | - |
| LXA₄ | ND | 0.27 | - |
| RvD1 | ND | 1.84 | - |
| All-trans-retinol | ND | 3.6 | 0.38 |
| Androsterone | ND | 29.5 | 150 |

Abbreviation: ND, not determined.

### Table 5

Substrate specificity of rat RDH7

| Substrate | Kₘ μM | Vₘₕ, pmol × min⁻¹ | Vₘₕ/Kₘ pmol/(min × μM) |
|-----------|-------|---------------------|------------------------|
| 12(S)-HETE | 0.76 ± 0.42 | 3.35 ± 0.53 | 4.4 |
| 15(S)-HETE | 0.10 ± 0.09 | 13.7 ± 2.7 | 137 |
| 9(S)-HODE | 0.18 ± 0.09 | 15.1 ± 2.2 | 84 |
| LTB₄ | ND | 0.23 | - |
| LXA₄ | ND | 0.61 | - |
| RvD1 | ND | 0.33 | - |
| All-trans-retinol | ND | 4.4 | - |
| Androsterone | ND | 34.4 | - |

Abbreviation: ND, not determined.

To establish whether the native endogenously expressed DHRS9 contributes to the metabolism of oxylipins, we generated a mouse model with targeted knockout of Dhirs9 gene. Dhirs9⁻/⁻ mouse strain has been generated by the UAB Transgenic Models Core via blastocyst injections of mouse embryonic stem cells carrying targeted allele of Dhirs9 gene obtained from NIH Knockout Mouse Project (KOMP) (Fig. 4A). The absence of DHRS9 protein in the skin microsomes from Dhirs9⁻/⁻ mice was confirmed by Western blot analysis (Fig. 4B). Dhirs9⁻/⁻ mice were viable and fertile and did not display an obvious phenotype under normal conditions.

### Generation of Dhirs9⁻/⁻ mice

To establish whether the native endogenously expressed DHRS9 contributes to the metabolism of oxylipins, we generated a mouse model with targeted knockout of Dhirs9 gene. Dhirs9⁻/⁻ mouse strain has been generated by the UAB Transgenic Models Core via blastocyst injections of mouse embryonic stem cells carrying targeted allele of Dhirs9 gene obtained from NIH Knockout Mouse Project (KOMP) (Fig. 4A). The absence of DHRS9 protein in the skin microsomes from Dhirs9⁻/⁻ mice was confirmed by Western blot analysis (Fig. 4B). Dhirs9⁻/⁻ mice were viable and fertile and did not display an obvious phenotype under normal conditions.

### LTB₄ and RvD1 dehydrogenase activities are reduced in Dhirs9⁻/⁻ mouse tissues

Previous studies suggested that the DHRS9 is highly expressed in the skin, lungs, and trachea (16, 23). In order to determine whether the absence of DHRS9 reduces the activities of microsomes from these tissues toward oxylipins, we first tested the microsomes from wild-type mice with a panel of oxylipins to identify the substrates that are metabolized by microsomes at a measurable rate. Significant activity was detected toward LTB₄ with microsomes from the skin; whereas the activities of lung and tracheal microsomes were at an order of magnitude lower (Fig. 5A). A comparison of microsomal activities of the skin from wild-type littermates versus Dhirs9⁻/⁻ mice showed a sixfold reduction in the rate of metabolic conversion of 1 μM LTB₄ with DHRS9-null microsomes. Tracheal microsomes displayed a fourfold decrease, and lung microsomes—a 1.7-fold decrease in the rate of LTB₄ oxidation compared with corresponding microsomes from the wild-type mice (Fig. 5).

A measurable oxidation rate by the skin and lung microsomes was also detected with 1 μM RvD1, whereas the rate with tracheal microsomes was about tenfold lower (Fig. 5B). DHRS9-null mice displayed significantly reduced activities toward 1 μM RvD1 for microsomes from the skin (2.4-fold) and trachea (2.5-fold). Together with in vitro assays showing...
that LTB4 and RvD1 are good substrates for the recombinant mouse DHRS9, the comparison of microsomal activities of DHRS9-null mice with the wild-type indicated that the extent of DHRS9 contribution to the oxidative activity of microsomal membranes toward LTB4 and RvD1 varies across mouse tissues.

Notably, in agreement with the lower activities of recombinant DHRS9 toward allopregnanolone and all-trans-retinol, there were no differences in the oxidation rates of allopregnanolone or all-trans-retinol between the microsomes isolated from tissues of wild-type mice compared with Dhrs9−/− mice (data not shown).

Discussion
Most of the studies published to date refer to DHRS9 as a retinol dehydrogenase based on the previously published reports (16–18, 36). However, as shown in the present study, DHRS9 is much more efficient toward oxylipins with hydroxyl groups at positions 12 and above than toward retinol or androsterone. It also appears that the members of the SDR9C
family have more divergent functions than the members of the SDR16C or SDR7C families, which primarily specialize in the oxidative (SDR16C) or reductive (SDR7C) metabolism of retinoids. Unlike human DHRS9, human RDH16 displayed much lower rates and higher $K_m$ values toward oxylipins than toward androsterone. This study utilized the same Sf9 micromosomal preparations of SDRs that were previously analyzed for their activity toward all-trans-retinol and 3α-hydroxysteroids as substrates (34). To determine whether there was a loss of activity during storage, the microsomes were retested with saturating concentrations of all-trans-retinol and androsterone. These assays demonstrated that no significant loss of activity had occurred; thus, the catalytic efficiency of SDRs toward C18-C22 polyunsaturated hydroxylipids can be compared with the previously published data on all-trans-retinol and androsterone.

Based on the previously reported parameters (34), the catalytic efficiency value ($V_{\text{max}}/K_m$) of microsomal preparations containing RDH16 toward androsterone was 24 pmol/(min × μM) and only ~0.1 pmol/(min × μM) toward all-trans-retinol (Table 3). Thus, androsterone appeared to be a much better substrate for RDH16 than all-trans-retinol and a somewhat better substrate than oxylipins, although RDH16 could potentially metabolize these compounds if they were more abundant than androsterone. In comparison, human HSD17B6 appeared to display a strong preference for androsterone compared with any other substrates tested. Its $V_{\text{max}}/K_m$ value for androsterone was 150 pmol/(min × μM) (Table 4) (10).

Since rat RDH7 was one of the founding members of the SDR9C family (6), we also examined its activity toward oxylipin substrates. To our surprise, this enzyme displayed high catalytic efficiency for the oxidation of 15(S)-HETE and 9(S)-HODE (Table 5), suggesting that rat RDH7 could participate in the oxidative metabolism of these substrates. Thus, like human RDH16, which is expressed primarily in the liver (9), the liver-specific rat RDH7 (6) may also contribute to the oxidation of oxylipins in a tissue-specific manner.

It should be noted that mice have more members of the SDR9C family than humans and rats (Fig. 1) (4). Several of these proteins, i.e., mouse RDH16, RDH7, and RDH9, were shown to exhibit catalytic activity toward 3α-hydroxysteroids and cis-retinols and were named cis-retinol/androgen dehydrogenases (CRAD) 1, 2, and 3, respectively (37–39). Whether these enzymes are also active toward oxylipins has not yet been reported; however, potentially, they could complement the activity of mouse DHRS9 in a tissue-specific manner.

This investigation identified human DHRS9 as the most potent oxylipin dehydrogenase among the tested human members of the SDR9C family. Importantly, the ability of DHRS9 to metabolize oxylipins seems to be conserved in mice, supporting the physiological relevance of DHRS9 in the metabolism of these compounds. Furthermore, activity assays using microsomes from mouse tissues show that the microsomal activity toward LTB4 and RvD1 is significantly decreased in the skin and trachea of DHRS9-null mice compared with wild-type mice, providing further evidence in support of DHRS9 role in metabolism of oxylipins.

Previous studies suggested that cytosolic NAD$^+$-dependent SDR36C1, 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which is the primary enzyme involved in metabolism of prostaglandins (40), also displays activity toward lipoxins and other 15-hydroxy lipoxygenase products (41–43). However, based on the published values for $V_{\text{max}}$ (18,083 nmol/(min × mg)) and $K_m$ (16 μM) (41), the catalytic efficiency 15-PGDH with 15(S)-HETE was 1130 pmol/(min × μM) when calculated based on the activity in samples containing 1 μg of purified 15-PGDH. In comparison, the $V_{\text{max}}$ value of partially purified human DHRS9 in Sf9 microsomes for 15(S)-HETE was 390 pmol/(min × μM). Based on our estimates, DHRS9 protein in this preparation constitutes 1/10th of the microsomal protein; hence, its catalytic efficiency for 15(S)-HETE is higher (~3900) than that of 15-PGDH. The membrane-bound DHRS9 might have an additional advantage over the cytosolic 15-PGDH in terms of its access to lipophilic substrates.

In fact, one of the intriguing possibilities with respect to the physiological role of DHRS9 might be its participation in the so-called 12-hydroxyeicosanoid dehydrogenase/10,11-reductase pathway, which was implicated in metabolism of 12(S)-HETE, LTB4, and possibly of 13(S)-HODE (44, 45). Pioneering studies carried out by Wainwright and Powell demonstrated that catabolic conversion of 12(S)-HETE and LTB4 is initiated when both compounds are rapidly oxidized by 12-hydroxyeicosanoid dehydrogenase followed by reductase of the 10,11-double bond by 10,11-reductase (44). Of prime significance, their biochemical characterization of 12-hydroxyeicosanoid dehydrogenase revealed that this is a microsomal NAD$^+$-dependent enzyme (44). Around this time in the 1990s, a cytosolic NADP$^+$-dependent LTB4 12-hydroxydehydrogenase was purified and cloned by Yokomizo et al. (46, 47). It turns out that this enzyme, one of the zinc-independent members of the medium-chain dehydrogenase/reductase (MDR) superfamily, is identical to prostaglandin 13-reductase (48). In view of the 10:1 relative abundance of NADPH over NADP$^+$ in cells, it is likely that its reductive functions predominate, and this is further suggested by recent direct analyses indicating 50-fold more efficient activity as a prostaglandin Δ13-reductase compared with its oxidation of LTB4 (49).

To our knowledge, to date, the molecular nature of the microsomal NAD$^+$-dependent 12-hydroxyeicosanoid dehydrogenase is not established. Based on the kinetic analysis reported here, it seems reasonable to propose that the 12-hydroxyeicosanoid dehydrogenase activity described by Wainwright and Powell might reflect the activity of microsomal DHRS9. If this is the case, it suggests that DHRS9 plays a pivotal role in metabolism of LTB4, which is a potent proinflammatory agent and, potentially, in metabolism of other oxylipins that had been identified as substrates of DHRS9 in this study. Certainly, as established by Yokomizo et al., (46) the oxidation of LTB4 to 12-oxo-LTB4 results in 100-fold loss of bioactivity, indicating that the reaction catalyzed by 12-hydroxyeicosanoid dehydrogenase can efficiently terminate LTB4 signaling.
Oxylipin dehydrogenase activity of DHRS9

The expression levels of DHRS9 in human and rodent tissues vary greatly depending on the underlying conditions. DHRS9 gene is frequently cited as a differentially expressed gene in such diseases as colorectal cancer (29), cicatricial allopedia (30), polycystic ovary syndrome (31), oral squamous cell carcinoma (32), rheumatoid arthritis (50), pancreatic cancer (51), etc. Consequently, examination of the physiological role of DHRS9 in the metabolism of oxylipins initiated with this study should shed light on the contribution of DHRS9 to pathophysiology of cancer progression and potentially other diseases linked to inflammation.

Experimental procedures

Reagents

Oxylipins were purchased from Cayman Chemical. Retinoids were purchased from Toronto Research Chemicals and steroids from Steraloids and Sigma.

Expression vectors

Constructs for expression of human DHRS9, RDH16, HSD17B6, RDH5, RDH10, HSD11B1, in Baculovirus system, as well as HEK293 cell stably expressing human DHRS9 were described previously (9, 10, 15, 21, 23). Vector containing cDNA encoding rat RDH7 was provided by Dr Gregg Duester at Sanford Burnham Prebys Medical Discovery Institute. For expression in Sf9 cells, RDH7 cDNA was subcloned in EcoRI–NotI sites of pVL1393 Baculovirus transfer vector.

Coding sequences of mouse and rat DHRS9 including the stop codons were amplified from the skin and heart cDNA, respectively, and cloned into BamHI – EcoRI sites of pCMV-Tag4a vector (Stratagene) without tags. The primers used for preparation of constructs are listed in Table S2.

Determination of kinetic constants

SDR proteins were expressed in Sf9 cells using the Baculovirus expression system as described previously and microsomal preparations containing the recombinant proteins were used for activity assays (9, 10, 15, 35). Steady-state kinetics were performed in 90 mM potassium phosphate, pH 7.3, and 40 mm KCl at 37 °C in siliconized glass tubes. Oxylipin substrates were added from 100× stocks prepared in ethanol with final concentration of ethanol in reactions 1%. The 500-μl reactions were started with the addition of cofactor and stopped by addition of 2.5 ml of methylene chloride (LTB4, RvD1, 17(R)-RvD1, RvE1, LXA4, LXB4), or 0.5 ml of ethyl acetate and 2 ml of hexane (12(S)-HETE, 15(S)-HETE, 9(S)-HODE, 13(S)-HODE, 14(S)-HDoHE). The aqueous phase was acidified to pH ~3.0 by the addition of 10 μl of 4N HCl to allow for the extraction of carboxylic acids. Samples were vortexed and centrifuged in a low-speed benchtop centrifuge to facilitate phase separation. Organic phases were collected, and solvent was evaporated under flow of N2. Dry residues were dissolved in 100 μl of the mobile phase solvent, and 50 μl of the samples was analyzed using reverse-phase HPLC. The HPLC system consisted of Waters e2695 separation module, Waters 2998 photodiode array detector, and Waters Symmetry C18 column, 4.4 × 150 mm, 3.5 μm (Waters). Separation was performed in the isocratic mode at 0.7 ml/min flow rate with 50:50 acetonitrile-water mobile phase for LTB4, RvD1, 17(R)-RvD1, RvE1, LXA4, LXB4, and with 80:20 acetonitrile:water mobile phase for the remaining compounds. Mobile phase also contained 0.01% of glacial acetic acid.

Chromatograms were extracted at maximum absorbance wavelength for each of the analyzed compounds. The under-the-curve areas of the substrate and product peaks were converted into molar amounts using linear regressions of the calibration curve obtained by the triplicate injections of four serial dilutions of each compound (covering range of 10–1250 pmol per injection) from the commercial stocks with known concentrations. Steady-state kinetics were performed in 90 mM potassium phosphate, pH 7.3, and 40 mm KCl at 37 °C in siliconized glass tubes using microsomal membranes containing individual SDR enzymes as described previously (9).

For determination of apparent \( K_m \), values, six concentrations between 0.25 and 16 μM were used for 12(S)-HETE and 13(S)-HODE; 0.125 to 16 μM for 15(S)-HETE and 9(S)-HODE; 0.125 to 1.25 μM for 14(S)-HDoHE; 0.125 to 4 μM for LTB4 and RvD1; and 0.125 to 8 μM for LXA4. Initial velocities (nmol of product formed/mg of microsomal protein) were obtained by linear regression. The amount of product formed was less than 15% within the 15-min reaction time and was linearly proportional to the amount of microsomes added. Each \( K_m \) determination was repeated at least three times. A control without added cofactor was included with each experiment.

Reference activity with ADT was determined as described in reference (10) using 5 μg of S9 microsomes containing the respective enzymes, which were incubated with 20 μM ADT and 1 mM NADH for 15 min in 500-μl reaction volume at 37 °C (Fig S2). The radiolabeled 5α-androstane-3α-ol-17one (androstosterone) (45 Ci/mmol) (NEN Life Science Products) was diluted with cold steroid (Sigma) to achieve the required specific radioactivity. Reference activities for all-trans-retinol were determined as described in (35) under the same conditions as for ADT except the concentration of all-trans-retinol was 10 μM.

Western blot analysis

Protein concentrations were determined using BioRad DC Protein Assay with BSA as a standard. Total protein homogenates or microsomal protein fraction as indicated was subjected to SDS-PAGE in 12% separating gel with 4% stacking gel. The gels were transferred to Immobilon-P PVDF membrane (Millipore) and blocked in 4% BSA in TBST buffer. Blots were incubated overnight at 4 °C in blocking buffer with the following primary antibodies: DHRS9 rabbit polyclonal antibody (#A6324, Abclonal) at 1:2000 dilution, cytochrome P450 reductase antibodies (#AB1257, Chemicon International) at 1:4000 dilution or with custom-made rabbit polyclonal DHRS9 antibodies (1:250), and cytochrome p450 antibodies ab #13513 (Abcam, 1:1000). Secondary goat anti-rabbit horseradish-peroxidase-conjugated antibody (#170-6515, Bio-Rad) was used at 1:10,000 dilution. Immunoreactive bands were visualized using the Pierce ECL Western Blotting Substrate (#32106, Thermo Scientific). Alternatively, ECL Plex goat anti-
rabbit Cy5 antibody (#GEPA45011, Sigma) was used at a 1:2500 dilution. Imaging was performed using ChemiDoc MP Imaging System (Bio-Rad). Blots were quantified with UN-SCAN-IT software (Silk Scientific Inc).

**Generation of Dhrs9<sup>−/−</sup> mice**

The studies were approved by the UAB IACUC Board. Mouse C57BL/6NTac ES cells carrying targeted knockout allele Dhrs9<sup>w1(KOMP)Vig</sup> were obtained from KOMP Repository at the University of California–Davis. The insertion of ZEN-UB1 targeting cassette in Dhrs9<sup>wm1(KOMP)Vig</sup> allele (Velocigene KOMP Definitive Null Allele Design #13240, http://velocigene.com/komp/detail/13240) leads to the deletion of 8577 bp on mouse chromosome 2 corresponding to 69,223,257 to 69,231,833 nt in the genome build GRCm39. The deleted fragment includes exons 2 to 5 of the reference transcript NM_175512 and eliminates an entire protein coding sequence of Dhrs9. The inserted 6084-bp cassette encodes a LacZ reporter expressed under the control of endogenous Dhrs9 promoter and neomycin selection marker under the control of human ubiquitin C promoter.

Chimeric animals were generated by the University of Alabama at Birmingham Transgenic and Genetically Engineered Models facility via ESC injection into albino C57BL/6J blastocysts. Male chimeras were crossed to wild-type C57BL6/J females to establish germ line transmission. Heterozygous founders were identified by PCR with Dhrs9-WTF (5’-GAT GGA TGA GTT TGC GTG TG-3’) and Dhrs9-WTR (5’-TCA GGA CCT TTA TGC CTG TTC-3’) primers for wild-type allele (942 bp product), and Dhrs9-WTF and (5’-GTC TGT CCT AGC TTC CTC ACT G-3’) primers—for knockout allele (504 bp product). The same primers were used for subsequent genotyping of progeny obtained from crossing of heterozygotes.

**Statistical analysis**

Statistical significance was determined using two-tailed unpaired t test.

**Data availability**

All data are contained within the manuscript.

---

**References**

1. Oppermann, U., Filling, C., Hult, M., Shaqat, N., Wu, X., Lindh, M., Shaqat, J., Nordling, E., Kalberg, Y., Persson, B., and Jörnvall, H. (2003) Short-chain dehydrogenases/reductases (SDR): The 2002 update. *Chem. Biol. Interact.* 143–144, 247–253

2. Jörnvall, H., Persson, B., Krook, M., Atian, S., Gonzalez-Duarte, R., Jeffery, J., and Ghosh, D. (1995) Short-chain dehydrogenases/reductases (SDR). *Biochemistry* 34, 6003–6013

3. Persson, B., Kalberg, Y., Bray, J. E., Bruford, E., Delaporta, S. L., Favia, A. D., Duarte, R. G., Jörnvall, H., Kavanagh, K. L., Kedishvili, N., Kisiela, M., Masar, E., Mindnich, R., Orchard, S., Penning, T. M., et al. (2009) The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. *Chem. Biol. Interact.* 178, 94–98

4. Belvaeva, O. V., and Kedishvili, N. Y. (2006) Comparative genomic and phylogenetic analysis of short-chain dehydrogenases/reductases with dual retinol/sterol substrate specificity. *Genomics* 88, 820–830

5. Simon, A., Hellman, U., Wernstedt, C., and Eriksson, U. (1995) The retinal pigment epithelial-specific 11-cis retinol dehydrogenase belongs to the family of short chain alcohol dehydrogenases. *J. Biol. Chem.* 270, 1107–1112

6. Chai, X., Boerman, M. H., Zhai, Y., and Napoli, J. L. (1995) Cloning of a cDNA for liver microsomal retinol dehydrogenase. A tissue-specific, short-chain alcohol dehydrogenase. *J. Biol. Chem.* 270, 3900–3904

7. Wang, J., Chai, X., Eriksson, U., and Napoli, J. L. (1999) Activity of human 11-cis-retinol dehydrogenase (Rdh5) with steroids and retinoids and expression of its mRNA in extra-ocular human tissue. *Biochem. J.* 338, 23–27

8. Biswas, M. G., and Russell, D. W. (1997) Expression cloning and characterization of oxidative 17beta- and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate. *J. Biol. Chem.* 272, 15959–15966

9. Gough, W. H., VanOoteghem, S., Sint, T., and Kedishvili, N. Y. (1998) cDNA cloning and characterization of a new human microsomal NAD<sup>+</sup>-dependent dehydrogenase that oxidizes all-trans retinol and 3α-hydroxysteroids. *J. Biol. Chem.* 273, 19778–19785

10. Chetyrkin, S. V., Hu, J., Gough, W. H., Dumnahul, N., and Kedishvili, N. Y. (2001) Further characterization of human microsomal 3α-hydroxysteroid dehydrogenase. *Arch. Biochem. Biophys.* 386, 1–10

11. Yamamoto, H., Simon, A., Eriksson, U., Harris, E., Berson, E. L., and Dryja, T. P. (1999) Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. *Nat. Genet.* 22, 188–191

12. Parker, R. O., and Crouch, R. K. (2010) Retinol dehydrogenases (RDHs) in the visual cycle. *Exp. Eye. Res.* 91, 788–792

---

**Oxylipin dehydrogenase activity of DHRS9**

K. R. G. visualization; O. V. B., S. E. W., K. M. P., A. R. B., and N. Y. K. writing—original draft; K. M. P., A. R. B., and N. Y. K. writing—reviewing and editing.

**Funding and additional information**—These studies were supported in part by the NIH grants AR076924 (N. Y. K.), CA210946 (N. Y. K.), and GM134548 (A. R. B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: 14(S)-HDoHE, 14(S)-hydroxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid; 12(S)-HETE, 12(S)-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoic acid; 15(S)-HETE, 15(S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid; 9(S)-HODE, 9S-hydroxy-10E,12Z-octadecadienoic acid; 13(S)-HODE, 13(S)-hydroxy-9Z,11E-octadecadienoic acid; LTB<sub>5</sub>, leukotriene B<sub>5</sub>; LXA<sub>4</sub>, lipoxin A<sub>4</sub>; RvD1, resolvin D1.
Oxylipin dehydrogenase activity of DHR9

13. Chen, W., Song, M. S., and Napoli, J. L. (2002) SDR-O: An orphan short-chain dehydrogenase/reductase localized at mouse chromosome 10/human chromosome 12. *Gene* 294, 141–146

14. Takeichi, T., Hirabayashi, T., Miyasaka, Y., Kawamoto, A., Okuno, Y., Taguchi, S., Tanahashi, K., Murase, C., Takama, H., Tanaka, K., Boeglin, W. E., Calcutt, M. W., Watanabe, D., Kono, M., Muro, Y., et al. (2020) SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation. *J. Clin. Invest.* 130, 890–903

15. Chetrykin, S. V., Belyaeva, O. V., Gough, W. H., and Kedivshilvi, N. Y. (2001) Characterization of a novel type of human microsomal 3alpha-hydroxyysteroid dehydrogenase: Unique tissue distribution and catalytic properties. *J. Biol. Chem.* 276, 22738–22786

16. Soref, C. M., Di, Y. P., Hayden, L., Zhao, Y. H., Satre, M. A., and Wu, R. (2001) Characterization of a novel airway epithelial cell-specific short chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinol. *J. Biol. Chem.* 276, 24194–24202

17. Rexer, B. N., and Ong, D. E. (2002) A novel short-chain alcohol dehydrogenase from rats with retinol dehydrogenase activity, cyclically expressed in uterine epithilium. *Biol. Reprod.* 65, 1555–1564

18. Wang, C., Kane, M. A., and Napoli, J. L. (2011) Multiple retinol and retinal dehydrogenases catalyze all-trans-retinoic acid biosynthesis in astrocytes. *J. Biol. Chem.* 286, 6542–6553

19. Zhao, Y., Vuckovic, M., Yoo, H. S., Fox, N., Rodriguez, A., McKessy, K., and Napoli, J. L. (2021) Retinoic acid exerts sexually dimorphic effects on muscle energy metabolism and function. *J. Biol. Chem.* 297, 101101

20. Cali, F., Elia, M., Vinci, M., Vetri, L., Correnti, E., Roccella, M., Vanadia, F., and Romano, V. (2020) Are mutations in the DHRS9 gene causally linked to epilepsy? A case report. *Medicina (Kaunas)* 56, 387–390

21. Belyaeva, O. V., Chetrykin, S. V., Clark, A. L., Kostereva, N. V., Santa-Cruz, K. S., Chronwall, B. M., and Kedivshilvi, N. Y. (2007) Role of microsomal retinol/sterol dehydrogenase-like short-chain dehydrogenases/reductases in the oxidation and epimerization of 3alpha-hydroxysteroids in human tissues. *Endocrinology* 148, 2148–2156

22. Sandell, L. L., Sanderson, B. W., Moiseyev, G., Johnson, T., Mushegian, A., Young, K., Rey, J. P., Ma, J. X., Staehling-Hampton, K., and Trainor, P. A. (2007) RDH10 is essential for synthesis of embryonic retinoic acid and is required for limb, craniofacial, and organ development. *Genes. Dev.* 21, 1113–1124

23. Lee, S. A., Belyaeva, O. V., Wu, L., and Kedivshilvi, N. Y. (2011) Retinol dehydrogenase 10 but not retinol/sterol dehydrogenase(s) regulates the expression of retinoic acid-responsive genes in human transgenic skin raft culture. *J. Biol. Chem.* 286, 13550–13560

24. Gao, Y., Zhang, E., Fei, X., Kong, L., Liu, P., and Tan, X. (2021) Identification of novel metabolism-associated subtypes for pancreatic cancer to establish an eighteen-gene risk prediction model. *Front. Cell Dev. Biol.* 9, 691161

25. Bai, S., Ye, R., Wang, C., Sun, P., Wang, D., Yue, Y., Wang, H., Wu, S., Yu, M., Xi, S., and Zhao, L. (2021) Identification of proteomic signatures in chronic obstructive pulmonary disease emphysematous phenotype. *Front. Mol. Biosci.* 8, 650064

26. Khalid, M., Idrichi, T., Seki, N., Wada, M., Yamada, Y., Fukushima, H., Toda, H., Kita, Y., Kawasaki, Y., Tanoue, K., Kurahata, H., M ataki, Y., Maemura, K., and Natsugoe, S. (2019) Gene regulation by antitumor barrier formation. *J. Clin. Invest.* 133, 325–333

27. Shimomura, H., Sasahira, T., Nakashima, C., Shimomura-Kurihara, M., and Kiriti, T. (2018) Downregulation of DHR9S is associated with poor prognosis in oral squamous cell carcinoma. *Pathology* 50, 642–647

28. Garcia-Garcia, A. B., Martinez-Hervas, S., Real, J. T., Marin-Garcia, P., de Marco, G., Priego, A., Martinez-Valls, J. F., Carnena, R., Chaves, F. J., and Ascaso, J. F. (2019) Gene expression profile following an oral unsaturated fat load in abdominal obese subjects. *Eur. J. Nutr.* 58, 1331–1337

29. Lapschina, E. A., Belyaeva, O. V., Chumakova, O. V., and Kedivshilvi, N. Y. (2003) Differential recognition of the free versus bound retinol by human microsomal retinol/sterol dehydrogenases: Characterization of the holo-CRBP dehydrogenase activity of RoDH-4. *Biochemistry* 42, 776–784

30. Belyaeva, O. V., Johnson, M. P., and Kedivshilvi, N. Y. (2008) Kinetic analysis of human enzyme RDH10 defines the characteristics of a physiologically relevant retinol dehydrogenase. *J. Biol. Chem.* 283, 20299–20308

31. Markova, N. G., Pinkas-Sarafova, A., Karaman-Jurukovska, N., Jurukovski, V., and Simon, M. (2003) Expression pattern and biochemical characteristics of a major epidermal retinol dehydrogenase. *Mol. Genet. Metab.* 78, 119–135

32. Chai, X., Zhai, Y., and Napoli, J. L. (1997) cDNA cloning and characterization of a cis-retinol/3alpha-hydroxysterol short-chain dehydrogenase. *J. Biol. Chem.* 272, 33125–33131

33. Su, J., Chai, X., Kahn, B., and Napoli, J. L. (1998) cDNA cloning, tissue distribution, and substrate characteristics of a cis-retinol/3alpha-hydroxysterol short-chain dehydrogenase isozyme. *J. Biol. Chem.* 273, 17910–17916

34. Zhuang, R., Lin, M., and Napoli, J. L. (2002) cis-Retinol/androgen dehydrogenase, isozyme 3 (CRAD3): A short-chain dehydrogenase active in a reconstituted path of 9-cis-retinoid acid biosynthesis in intact cells. *Biochemistry* 41, 3477–3483

35. Tai, H. H., Cho, H., Tong, M., and Ding, Y. (2006) NAD+-linked 15-hydroxyprostaglandin dehydrogenase: Structure and biological functions. *Curr. Pharm. Des.* 12, 955–962

36. Bergholte, J. M., Soberman, R. J., Hayes, R., Murphy, R. C., and Okita, R. T. (1987) Oxidation of 15-hydroxyicosatetraenoic acid and other hydroxy fatty acids by lung prostaglandin dehydrogenase. *Arch. Biochem. Biophys.* 257, 444–450

37. Clish, C. B., Levy, B. D., Chiang, N., Tai, H. H., and Serhan, C. N. (2000) Oxidoreductases in lipoxin A4 metabolic inactivation: A novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. *J. Biol. Chem.* 275, 25372–25380

38. Sun, Y. P., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., Colgan, S. P., Petasis, N. A., and Serhan, C. N. (2007) Resolvin D1 and its aspirin-triggered 15R eipmer. Stereocchemical assignments, anti-inflammatory properties, and enzymatic inactivation. *J. Biol. Chem.* 282, 9323–9334

39. Wainwright, S. L., and Powell, W. S. (1991) Mechanism for the formation of dihydro metabolites of 12-hydroxycicosanoids. Conversion of leukotriene B4 and 12-hydroxy-5,14-eicosatetraenoic acid to 12-oxo intermediates. *J. Biol. Chem.* 266, 20899–20906

40. Wainwright, S. L., Falck, J. R., and Powell, W. S. (1990) Stereochemistry of leukotriene B4 metabolites formed by the reductase pathway in porcine polymorphonuclear leukocytes: Inversion of stereochemistry of the 12-hydroxy group. *Biochemistry* 29, 1180–1185

41. Yokomizo, T., Izumi, T., Takahashi, T., Kasa, T., Kobayashi, Y., Sato, F., Taketani, Y., and Shimizu, T. (1993) Enzymatic inactivation of leukotriene B4 by a novel enzyme found in the porcine kidney.
Oxylipin dehydrogenase activity of DHRS9

Puriﬁcation and properties of leukotriene B4 12-hydroxydehydrogenase. *J. Biol. Chem.* **268**, 18128–18135

47. Yokomizo, T., Ogawa, Y., Uozumi, N., Kume, K., Izumi, T., and Shimizu, T. (1996) cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. *J. Biol. Chem.* **271**, 2844–2850

48. Tai, H. H., Ensor, C. M., Tong, M., Zhou, H., and Yan, F. (2002) Prostaglandin catabolizing enzymes. *Prostaglandins Other Lipid Mediat.* **68-69**, 483–493

49. Mesa, J., Alsina, C., Oppermann, U., Parés, X., Farrés, J., and Porté, S. (2015) Human prostaglandin reductase 1 (PGR1): Substrate speciﬁcity, inhibitor analysis and site-directed mutagenesis. *Chem. Biol. Interact.* **234**, 105–113

50. Zhang, D., Li, Z., Zhang, R., Yang, X., Zhang, D., Li, Q., Wang, C., Yang, X., and Xiong, Y. (2020) Identiﬁcation of differentially expressed and methylated genes associated with rheumatoid arthritis based on network. *Autoimmunity* **53**, 303–313

51. Li, H. B., Zhou, J., Zhao, F., Yu, J., and Xu, L. (2020) Prognostic impact of DHRS9 overexpression in pancreatic cancer. *Cancer Manag. Res.* **12**, 5997–6006

52. Saitou, N., and Nei, M. (1987) The neighbor-joining method: A new method for reconstructing phylogenetic trees. *Mol. Biol. Evol.* **4**, 406–425

53. Kumar, S., Stecher, G., Li, M., Knyaz, C., and Tamura, K. (2018) MEGA X: Molecular evolutionary genetics analysis across computing platforms. *Mol. Biol. Evol.* **35**, 1547–1549